Management of Prednisone-Refractory Gout

Diagnostic Considerations

The American College of Rheumatology recommends reconsidering the diagnosis to rule out alternative conditions after three weeks of treatment failure with prednisone, and switching to a different anti-inflammatory monotherapy or adding a second agent as combination therapy, while ensuring the patient is on appropriate urate-lowering therapy with prophylaxis 1
Three weeks represents a treatment failure by any definition, as acute gout typically responds within 24-72 hours to appropriate therapy 1

The American College of Rheumatology recommends switching to another first-line agent when initial therapy fails, such as NSAIDs at full FDA-approved doses if no renal, cardiovascular, or gastrointestinal contraindications exist 2
Colchicine (1 mg loading dose followed by 0.5 mg one hour later, then 0.5 mg twice daily) is recommended if within reasonable timeframe from flare onset and no severe renal impairment (GFR >30 mL/min) 1, 2
Avoid colchicine in patients on strong CYP3A4/P-glycoprotein inhibitors (cyclosporine, clarithromycin) due to fatal toxicity risk 2
Acceptable combinations include oral corticosteroids plus colchicine, or colchicine plus NSAIDs 1, 2
Avoid NSAIDs plus systemic corticosteroids due to synergistic gastrointestinal toxicity 1
Intra-articular corticosteroid injection can be combined with any oral agent for monoarticular or oligoarticular disease 1, 2

Anakinra 100 mg subcutaneously daily for 3 consecutive days (Evidence B, though off-label) is recommended for patients who fail multiple conventional therapies 1
Canakinumab 150 mg subcutaneously (Evidence A, though not FDA-approved for gout at time of guideline publication) is recommended for patients who fail multiple conventional therapies 1, 2
The American College of Rheumatology notes uncertainty about risk-benefit ratio and recommends these only after failure of conventional agents 1
Current infection is an absolute contraindication to IL-1 inhibitor use 2

A three-week acute flare strongly suggests inadequate disease control and mandates initiation or optimization of urate-lowering therapy 3
Start allopurinol at ≤100 mg/day, increasing by 100 mg increments every 2-4 weeks to achieve target serum urate <360 µmol/L (6 mg/dL), or <300 µmol/L (5 mg/dL) for severe/recurrent gout 3
The American College of Rheumatology conditionally recommends starting ULT during an acute flare with appropriate anti-inflammatory coverage, as it does not significantly prolong flare duration 3

First-line options for prophylaxis include colchicine 0.6 mg once or twice daily, NSAIDs at prophylactic doses, or low-dose prednisone ≤10 mg/day 3, 4
Duration of prophylaxis should be for minimum 3-6 months after initiating ULT, or longer if tophi present 3, 4
Prophylaxis for <3 months is associated with flare spikes upon discontinuation 3
Low-dose prednisone (≤10 mg/day) is appropriate as second-line prophylaxis when colchicine and NSAIDs are contraindicated or ineffective 4, 2

Corticosteroids remain the safest option with no dose adjustment required in patients with severe renal impairment (GFR <30 mL/min) 2
Avoid colchicine entirely due to fatal toxicity risk in patients with severe renal impairment (GFR <30 mL/min) 2
Avoid NSAIDs due to acute kidney injury risk in patients with severe renal impairment (GFR <30 mL/min) 2
Oral corticosteroids are safer than NSAIDs due to cardiovascular risks of NSAIDs in patients with cardiovascular disease 2
Consider intra-articular injection for monoarticular disease to minimize systemic exposure in patients with cardiovascular disease 2
Monitor blood glucose more frequently during corticosteroid therapy in patients with diabetes 2
Consider NSAIDs or colchicine as alternatives if glucose control is problematic in patients with diabetes 2